Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation

Navin Wadehra, Sherif Farag, Brian Bolwell, Patrick Elder, Sam Penza, Matt Kalaycio, Belinda Avalos, Brad Pohlman, Guido Marcucci, Ronald Sobecks, Thomas Lin, Steven Andrèsen, Edward Copelan

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD). The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14 mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and relapsed HD. One hundred twenty-seven patients with a median age of 33 years (range, 14-67 years) underwent transplantation. The regimen was well tolerated, with 5.5% treatment-related mortality at 100 days after transplantation. With a median follow up of 6.7 years, the 5-year progression-free survival was 48 ± 5%, and the 5-year overall survival was 51 ± 5%. A Cox proportional hazards model identified refractory disease at time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk >10 cm affected overall survival. Five patients died between 5.3 and 9.3 years of late complications, including secondary myelodysplasia or acute myeloid leukemia, secondary solid malignancies, and pulmonary toxicity. This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality.

Original languageEnglish
Pages (from-to)1343-1349
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume12
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Busulfan
Stem Cell Transplantation
Etoposide
Hodgkin Disease
Cyclophosphamide
Transplantation
Survival
Mortality
Proportional Hazards Models
Acute Myeloid Leukemia
Disease-Free Survival
Radiation
Recurrence
Lung
Therapeutics
Neoplasms

Keywords

  • Autotransplant
  • Busulfan
  • Hodgkin's disease

ASJC Scopus subject areas

  • Transplantation

Cite this

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation. / Wadehra, Navin; Farag, Sherif; Bolwell, Brian; Elder, Patrick; Penza, Sam; Kalaycio, Matt; Avalos, Belinda; Pohlman, Brad; Marcucci, Guido; Sobecks, Ronald; Lin, Thomas; Andrèsen, Steven; Copelan, Edward.

In: Biology of Blood and Marrow Transplantation, Vol. 12, No. 12, 12.2006, p. 1343-1349.

Research output: Contribution to journalArticle

Wadehra, N, Farag, S, Bolwell, B, Elder, P, Penza, S, Kalaycio, M, Avalos, B, Pohlman, B, Marcucci, G, Sobecks, R, Lin, T, Andrèsen, S & Copelan, E 2006, 'Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation', Biology of Blood and Marrow Transplantation, vol. 12, no. 12, pp. 1343-1349. https://doi.org/10.1016/j.bbmt.2006.08.039
Wadehra, Navin ; Farag, Sherif ; Bolwell, Brian ; Elder, Patrick ; Penza, Sam ; Kalaycio, Matt ; Avalos, Belinda ; Pohlman, Brad ; Marcucci, Guido ; Sobecks, Ronald ; Lin, Thomas ; Andrèsen, Steven ; Copelan, Edward. / Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation. In: Biology of Blood and Marrow Transplantation. 2006 ; Vol. 12, No. 12. pp. 1343-1349.
@article{1c00b6a013ac4c748605ea3902504aa9,
title = "Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation",
abstract = "Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD). The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14 mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and relapsed HD. One hundred twenty-seven patients with a median age of 33 years (range, 14-67 years) underwent transplantation. The regimen was well tolerated, with 5.5{\%} treatment-related mortality at 100 days after transplantation. With a median follow up of 6.7 years, the 5-year progression-free survival was 48 ± 5{\%}, and the 5-year overall survival was 51 ± 5{\%}. A Cox proportional hazards model identified refractory disease at time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk >10 cm affected overall survival. Five patients died between 5.3 and 9.3 years of late complications, including secondary myelodysplasia or acute myeloid leukemia, secondary solid malignancies, and pulmonary toxicity. This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality.",
keywords = "Autotransplant, Busulfan, Hodgkin's disease",
author = "Navin Wadehra and Sherif Farag and Brian Bolwell and Patrick Elder and Sam Penza and Matt Kalaycio and Belinda Avalos and Brad Pohlman and Guido Marcucci and Ronald Sobecks and Thomas Lin and Steven Andr{\`e}sen and Edward Copelan",
year = "2006",
month = "12",
doi = "10.1016/j.bbmt.2006.08.039",
language = "English",
volume = "12",
pages = "1343--1349",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation

AU - Wadehra, Navin

AU - Farag, Sherif

AU - Bolwell, Brian

AU - Elder, Patrick

AU - Penza, Sam

AU - Kalaycio, Matt

AU - Avalos, Belinda

AU - Pohlman, Brad

AU - Marcucci, Guido

AU - Sobecks, Ronald

AU - Lin, Thomas

AU - Andrèsen, Steven

AU - Copelan, Edward

PY - 2006/12

Y1 - 2006/12

N2 - Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD). The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14 mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and relapsed HD. One hundred twenty-seven patients with a median age of 33 years (range, 14-67 years) underwent transplantation. The regimen was well tolerated, with 5.5% treatment-related mortality at 100 days after transplantation. With a median follow up of 6.7 years, the 5-year progression-free survival was 48 ± 5%, and the 5-year overall survival was 51 ± 5%. A Cox proportional hazards model identified refractory disease at time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk >10 cm affected overall survival. Five patients died between 5.3 and 9.3 years of late complications, including secondary myelodysplasia or acute myeloid leukemia, secondary solid malignancies, and pulmonary toxicity. This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality.

AB - Busulfan (Bu)-based preparative regimens have not been extensively investigated in Hodgkin disease (HD). The purposes of this study were to investigate the toxicity and efficacy of a novel preparative regimen of Bu 14 mg/kg, etoposide 50-60 mg/kg, and cyclophosphamide 120 mg/kg in patients with primary refractory and relapsed HD. One hundred twenty-seven patients with a median age of 33 years (range, 14-67 years) underwent transplantation. The regimen was well tolerated, with 5.5% treatment-related mortality at 100 days after transplantation. With a median follow up of 6.7 years, the 5-year progression-free survival was 48 ± 5%, and the 5-year overall survival was 51 ± 5%. A Cox proportional hazards model identified refractory disease at time of transplantation as the only significant factor affecting relapse and overall survival, whereas disease bulk >10 cm affected overall survival. Five patients died between 5.3 and 9.3 years of late complications, including secondary myelodysplasia or acute myeloid leukemia, secondary solid malignancies, and pulmonary toxicity. This novel Bu regimen is comparable to other radiation-free preparative regimens in its effectiveness in the control of HD and with a low-risk of early treatment-related mortality.

KW - Autotransplant

KW - Busulfan

KW - Hodgkin's disease

UR - http://www.scopus.com/inward/record.url?scp=33845255237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845255237&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2006.08.039

DO - 10.1016/j.bbmt.2006.08.039

M3 - Article

C2 - 17162217

AN - SCOPUS:33845255237

VL - 12

SP - 1343

EP - 1349

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 12

ER -